J&J will acquire Halda Therapeutics in a $3.05B deal, adding prostate cancer therapy HLD-0915 and expanding its oncology ...

After laying off most of its staff and partnering away its phase 3 cancer asset earlier this year, precision oncology outfit ...

Analyst highlights three biotech stocks with major cancer-therapy catalysts and novel drug platforms, including key data ...

A San Diego biotech has set out to solve the formula for best-in-class antibody-drug conjugates, raising $120 million with ...

The FDA approved a drug made by Kura Oncology to treat patients with a certain type of genetically altered leukemia.

BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- General Oncology, Inc., a clinical-stage biopharmaceutical company dedicated to pioneering first-in-class medicines for metastatic cancers, today announced ...

The MarketWatch News Department was not involved in the creation of this content. AUSTIN, Texas and TOKYO, Oct. 3, 2025 /PRNewswire/ -- According to DataM Intelligence, the Active Pharmaceutical ...

At two upcoming events, experts will offer practical solutions to key challenges for oncology and rare disease clinical ...

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Cardiff Oncology, Inc. (NASDAQ:CRDF) stands against other hot biotech stocks under ...

We recently compiled a list of the 10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. In this article, we are going to take a look at where Kura Oncology, Inc.

JPMorgan raised the firm’s price target on Olema Oncology (OLMA) to $32 from $29 and keeps an Overweight rating on the shares. The firm adjusted ...